Immunocore expects to pay about $120 mln in sales-related rebate accruals in H2 2026
Company sees three growth areas for KIMMTRAK, including further market penetration and label expansion
Topline data from Phase 3 TEBE-AM trial could come as early as end of 2026
Result drivers and analyst coverage
Higher sales volumes - Co said Q2 KIMMTRAK revenue growth was primarily due to increased sales volumes in US and international regions
Market penetration - Co cited continued US community and global market penetration in metastatic uveal melanoma as a key growth driver
Clinical data impact - Five-year overall survival data for KIMMTRAK underscored lasting impact and reinforced confidence in platform, per CEO Bahija Jallal
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Miss
-$0.02
$0.01 (13 Analysts)
Q2 Net Income
Miss
-$808,000
$1.08 mln (11 Analysts)
Q2 Operating Income
Beat
-$3 mln
-$3.20 mln (12 Analysts)
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
IMCR•
